FOLH1 and prostate carcinoma: Should a primary prostatic cancer show PSMA-expression, a PSMA+ and PSMA- finding will be characterized as secondary lesion or treated as unimportant/benign lesion respectively in the fragment of an imaging technic with high negative predictive value (16).